Detail akcie Tarsus Pharma Rg online

Business Summary: Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tarsus Pharmaceuticals Inc revenues increased from $116.5M to $299.7M. Net loss decreased 37% to $58M. Revenues reflect BIOLOGICAL PRODUCTS segment increase of 55% to $181M. Lower net loss reflects BIOLOGICAL PRODUCTS segment loss decrease of 50% to $48.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.50 to -$1.41.